New PET Tracer Spots More Liver Metastases Than Standard Imaging in Neuroendocrine Tumors

Neuroendocrine tumors are rare, slow-growing malignancies that often fly under the clinical radar until they have already spread, most frequently to the liver. For decades, the backbone of their molecular imaging has been positron emission tomography with gallium-68-labeled somatostatin analogs such as DOTA-TATE, which bind to the somatostatin receptor subtype 2 that these tumors overexpress in abundance. Now a prospective head-to-head study published in the European Journal of Nuclear Medicine and Molecular Imaging suggests that a newer fluorine-18-labeled tracer paired with magnetic resonance imaging may outperform the established workhorse, detecting dramatically more lesions and offering sharper contrast between tumor and healthy tissue.

The study, led by researchers at Peking University Cancer Hospital and Institute in Beijing, enrolled forty-one patients with biopsy-proven neuroendocrine tumors. Every participant underwent both a [68Ga]Ga-DOTA-TATE PET/CT scan and a [18F]AlF-NOTA-JR11 PET/MR examination. JR11, also known as opsomat, is a somatostatin receptor antagonist rather than an agonist, a distinction that matters at the molecular level. Whereas agonist tracers bind preferentially to receptors in an active state and trigger their internalization, antagonists can bind to a larger pool of receptor conformations without activating them, potentially painting a brighter, more complete picture of receptor expression across tumor cells.

The headline result was stark. Across the study population, [18F]AlF-NOTA-JR11 PET/MR depicted 924 lesions in total, compared with 580 lesions detected by [68Ga]Ga-DOTA-TATE PET/CT, a difference the authors reported as highly significant. The advantage was driven overwhelmingly by liver metastases, where the new tracer identified 754 lesions against 405 for the incumbent. Primary tumor detection was similar between the two modalities, with 29 versus 25 primaries found, and there were no significant differences in the detection of lymph node or bone metastases. When the analysis shifted to the patient level, the pattern held: seventy-six percent of patients, thirty-one of the forty-one, had more lesions visualized on the fluorine-18 antagonist scan.

Size matters in these comparisons, and the investigators examined it carefully. The 405 liver metastases seen on both scans were significantly larger, with a median diameter of 14 millimeters, than the 349 lesions seen exclusively on [18F]AlF-NOTA-JR11, whose median diameter was just 6 millimeters. In other words, much of the incremental yield came from tiny sub-centimeter deposits, precisely the kind of small-volume disease that can alter staging, shape decisions about liver-directed therapies, and influence eligibility for peptide receptor radionuclide therapy.

Quantitative imaging metrics told an equally interesting story. Maximum standardized uptake values, the conventional measure of tracer avidity, were actually lower for [18F]AlF-NOTA-JR11 in primary tumors, liver metastases, and bone metastases compared with [68Ga]Ga-DOTA-TATE. That initially counterintuitive finding makes sense once background activity is considered. The fluorine-18 antagonist scan showed significantly lower uptake in normal tissues, and consequently a higher tumor-to-background ratio in primary tumors, lymph node metastases, and liver metastases. A dimmer background against which tumors glow brightly is often more valuable diagnostically than a raw measure of tracer accumulation, because it is contrast, not absolute intensity, that lets a radiologist resolve a lesion from its surroundings.

The chemistry behind the new tracer also carries practical significance. Gallium-68 is produced in a generator, which is convenient but constrains throughput and shelf life, since the isotope decays with a half-life of roughly sixty-eight minutes. Fluorine-18, by contrast, has a half-life of about 110 minutes and can be manufactured in cyclotron facilities with multi-center distribution, mirroring the logistics that made fluorodeoxyglucose the most widely used PET tracer in the world. The aluminum fluoride labeling method used to attach fluorine-18 to the NOTA-chelated peptide is a one-step, aqueous procedure that avoids the harsher conditions required for direct fluorination, making synthesis simpler and more amenable to routine production.

Pairing the tracer with magnetic resonance rather than computed tomography adds a second layer of advantage. MR provides superior soft-tissue contrast, particularly in the liver and abdomen, where diffusion-weighted and hepatobiliary sequences can flag lesions that CT misses. Previous work comparing PET/MR with PET/CT in oncology has shown that the combined modality can change patient management in a meaningful fraction of cases, and neuroendocrine tumors, with their hepatic predilection, stand to benefit most. The Beijing team’s design, in which the superior antagonist tracer is coupled with the superior anatomical imaging platform, deliberately stacks the deck toward maximal lesion conspicuity.

The study builds on a decade of clinical exploration of somatostatin receptor antagonists. Early proof-of-principle work demonstrated that antagonist-based imaging was feasible in humans, and subsequent head-to-head trials of gallium-68-labeled JR11 formulations against agonist tracers showed higher detection rates in metastatic, well-differentiated tumors. A parallel European study comparing a fluorine-18-labeled octreotide antagonist on PET/MR with gallium-68 DOTA-TATE PET/CT reported similar directional findings. What the new study adds is the first clinical comparison of aluminum fluoride-labeled JR11 on PET/MR, consolidating the tracer chemistry, the antagonist pharmacology, and the MR platform into a single evaluation.

Caveats remain before the findings translate into wholesale clinical practice. The cohort of forty-one patients, while adequate for a paired-lesion comparison, is modest, and the study came from a single center with radiopharmaceutical expertise in-house. The researchers did not report changes in patient management attributable to the additional lesions, so the downstream clinical impact of finding more small liver metastases, whether it prolongs survival or simply reshapes surveillance, awaits longitudinal follow-up. The authors also note that one co-author holds a position with a medical imaging company and contributed protocol optimization, although the remaining authors declared no competing interests.

Even so, the evidence positions [18F]AlF-NOTA-JR11 PET/MR as a serious contender to become the next generation of somatostatin receptor imaging. With more than four hundred additional liver lesions visualized across forty-one patients, higher tumor-to-background contrast, and a cyclotron-friendly isotope that could democratize distribution, the combination addresses the two great bottlenecks of current practice: sensitivity for small-volume hepatic disease and the supply chain constraints of gallium-68. For patients with neuroendocrine tumors, whose treatment decisions hinge on a precise map of where their disease has spread, a sharper and more widely available imaging lens could not arrive at a better time.

Subject of Research: Head-to-head comparison of fluorine-18 somatostatin receptor antagonist PET/MR and gallium-68 DOTA-TATE PET/CT for imaging neuroendocrine tumors

Article Title: Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors

Article References: Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. (n.d.). https://doi.org/10.1007/s00259-026-08176-8

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08176-8

Keywords: neuroendocrine tumors, PET/MR, PET/CT, somatostatin receptor antagonist, fluorine-18, gallium-68, DOTA-TATE, liver metastases, molecular imaging, nuclear medicine, tumor-to-background ratio, radiopharmaceuticals